EUDA Health Holdings Limited (NASDAQ: EUDA) received a formal delisting notice from Nasdaq’s Listing Qualifications Department on April 23, 2026. The notice states that the company has failed to maintain the minimum market value of listed securities of $35 million for 32 consecutive business days. Nasdaq has granted a 180‑day compliance period that ends on October 20, 2026, during which EUDA must restore the market value threshold for at least ten consecutive business days to avoid delisting.
EUDA’s market capitalization has fallen to $26.71 million, well below the $35 million threshold, and the company’s financial performance has been weak. In 2024, revenue was $4.01 million, up 8.22 % from the prior year, but net loss widened to $15.36 million, a 53 % increase. In the first half of 2025, revenue rose to $3.057 million, driven by growth in property management and wellness product sales, yet net income remained negative at $1.204 million compared with a $1.471 million profit in the prior quarter.
The decline in market value reflects challenges across EUDA’s two main segments. Property management services have faced increased operating costs and reduced occupancy rates, while the holistic wellness consumer products line has struggled to achieve scale in a competitive Asian market. The company has also pursued a 1‑for‑20 reverse stock split effective March 23, 2026, in an effort to lift the share price and meet listing requirements, and has launched a nationwide stem‑cell extraction platform in China to diversify revenue streams.
Under Nasdaq’s Capital Market rules, a company must demonstrate a market value of listed securities of at least $35 million for ten consecutive business days to regain compliance. The 180‑day window gives EUDA time to raise capital, improve profitability, or restructure its operations. If the company fails to meet the threshold, Nasdaq will initiate a delisting process that could remove EUDA’s shares from the Nasdaq Capital Market, severely limiting liquidity for investors.
The delisting notice has heightened scrutiny of EUDA’s financial health. Market participants have noted the company’s market capitalization is $26.71 million, well below the $35 million threshold, and the company’s financial performance has been weak. Investors are concerned that the company’s ongoing losses and the need for a reverse split signal limited growth prospects and potential liquidity constraints.
EUDA’s management has not issued a detailed plan to address the compliance deficiency, but the reverse split and recent capital‑raising activities suggest the company is attempting to stabilize its share price and meet Nasdaq’s requirements. However, without a clear turnaround strategy, the risk of delisting remains high, and the company’s future as a publicly listed entity is uncertain.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.